# Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus.

> PubMed lists PMID 40914786 in Drug delivery and translational research as Journal Article, Review, with publication-date metadata of 2025-09-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40914786-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40914786-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-40914786-liraglutide-v1.json
- Content SHA-256: `260ed4d8a612e04dc50d1a293ba5eddd15adb4e19804a9c197ec47373687f1c1`

## Claims and source pins

### Headline

Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus. ([`pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e`](#source-pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e))

### Summary

PubMed lists PMID 40914786 in Drug delivery and translational research as Journal Article, Review, with publication-date metadata of 2025-09-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e`](#source-pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e))

### Paragraph 1

PubMed lists PMID 40914786 in Drug delivery and translational research as Journal Article, Review, with publication-date metadata of 2025-09-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e`](#source-pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e`](#source-pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e))

## Sources

<a id="source-pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e"></a>
- **Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus. · retained source version 1:2026-06-01:current:f95fdb4a332ee95ea94f2c23147f3f1f7d79a65c8f745764c6dcc3ce021a9bb3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40914786/) (`pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-40914786-liraglutide-v1.json SHA-256: 260ed4d8a612e04dc50d1a293ba5eddd15adb4e19804a9c197ec47373687f1c1.